PD-1 and CTLA-4 double-target inhibitory polypeptide or its derivative, pharmaceutically acceptable salt and application thereof
CN122011130BActive Publication Date: 2026-07-10TENCENT TECHNOLOGY (SHENZHEN) CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TENCENT TECHNOLOGY (SHENZHEN) CO LTD
- Filing Date
- 2026-04-14
- Publication Date
- 2026-07-10
AI Technical Summary
Technical Problem
Existing technologies struggle to balance the binding affinity and molecular stability of both PD-1 and CTLA-4 targets, resulting in poor clinical treatment outcomes.
Method used
Develop a dual-target inhibitory peptide for PD-1 and CTLA-4 or its derivatives. Optimize the amino acid sequence through precise calculations and deep learning models to design peptides with high affinity and bioactivity that can bind to both PD-1 and CTLA-4 simultaneously, blocking their interaction with ligands.
Benefits of technology
It significantly enhances the immune response, relieves the inhibitory effect of immune checkpoint proteins, effectively treats or prevents related diseases, and can be used for qualitative and quantitative detection of PD-1 and CTLA-4.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122011130B_ABST
Abstract
The application relates to the technical field of biopharmaceuticals, and particularly discloses a PD-1 and CTLA-4 double-target inhibiting polypeptide or derivative, pharmaceutically acceptable salt and application thereof, wherein the amino acid sequence of the polypeptide is shown as SEQ ID NO:1. The polypeptide or derivative, pharmaceutically acceptable salt thereof can simultaneously bind to PD-1 and CTLA-4, can effectively block the combination between PD-1 and CTLA-4 and their ligands, can release the inhibition of immune checkpoint proteins PD-1 and CTLA-4 on immune cells, and can significantly enhance the immune response of the body. The polypeptide or derivative, pharmaceutically acceptable salt thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases caused by PD-1 and / or CTLA-4.
Need to check novelty before this filing date? Find Prior Art